Endocrinology & Diabetes

Dr. Arturo Solís Herrera, MD, PhD., has been Graduated from Institute Polytechnic Nacional, from CDMX, in 1978 as Medicine Doctor, with the specialties including Ophthalmology, in the National University of Mexico, and Neuro-Ophthalmology, at INNN, México. Later on he obtained his Master Science Degree from University of Aguascalientes, México, and thereafter a PhD in Pharmacology, Universidad de Guadalajara, México. Dr. Solís Herrera is director and founder of Human Photosynthesis® Research Center, in Ags., México, in 2007; where he has continued his research until today.

The discovery of a biochemical process, that from a molecule that exists on the skin, hair and coating the human retina but can be produced artificially, (melanin or polihidroxiindol), is capable of breaking the molecule water, separating the hydrogen and oxygen and extracting energy from this process. The raw material of this invention is abundant in nature, as its core components are water and a molecule that exists in the skin, hair and the lining of the human retina, but that can be produced artificially: melanin or polihidroxiindol.

Mikhail G Kolonin is an Associate Professor and Director of the Center for Metabolic and Degenerative Diseases at the University of Texas in Houston. As a PhD from Wayne State University, he pioneered the concept of expressing peptides disrupting protein interactions in animals. As a Postdoctoral fellow at MD Anderson Cancer Center, he screened combinatorial libraries to identify druggable cell surface markers. Based on this approach, he has invented experimental therapeutics for obesity and cancer. He is an Author of over 60 publications, and has editorial positions with Molecular Carcinogenesis and Cancer Research. He is endowed with a Distinguished University Chair in Metabolic Disease Research.

He has invented experimental therapeutics for obesity and cancer. He is an Author of over 60 publications, and has editorial positions with Molecular Carcinogenesis and Cancer Research. He is endowed with a Distinguished University Chair in Metabolic Disease Research.

Douglas N Ishii received his BA in Biochemistry from University of California, Berkeley and PhD in Pharmacology from Stanford University Medical School and conducted Postdoctoral work in Neurobiology at Stanford. He became Assistant then Associate Professor of Pharmacology at Columbia University, New York City. He is a Professor of Biomedical Sciences at Colorado State University. He served on various scientific study sections for National Science Foundation, National Institutes of Health and The Juvenile Diabetes International Foundation. Press coverage on his laboratory’s research on pathogenesis of diabetic neurological complications, and cause of brain atrophy in Alzheimer’s disease, includes articles in Der Spiegel, Hong Kong Standard, NY Times, LA Times, Denver Post, Chicago Tribune, ABC News, Forbes News, USA. Today, National Public Radio, and elsewhere. Nineteen patents were awarded based on this research.

laboratory’s research on pathogenesis of diabetic neurological complications, and cause of brain atrophy in Alzheimer’s disease.

Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews

Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews

Dr. Collino was born in Italy, on 19th January 1973. Degree in Pharmaceutical Chemistry and Technology at the University of Turin, Faculty of Pharmacy, March 1998: summa cum laude. Ph. D. in “Pharmacology and Toxicology” at the University of Turin, 1998 – 2002. Visiting Scientist at The William Harvey Research Institute, Centre for Experimental Medicine, Nephrology & Critical Care, Barts and The London, Queen Mary\s School of Medicine and Dentistry, London (UK) in the years 2003-2004. Since 2002 Assistant Professor of Pharmacology, Faculty of Pharmacy, University of Turin. Member of the Italian Society of Pharmacology, the European Biomedical Research Association. , British Pharmacological Society, European Shock Society.

His research activity is focused mainly on the investigation of innovative pharmacological strategies for metabolic disorders and the related cardiovascular complications.

Andres Fontalba Navas has completed his PhD in Medicine from Malaga University in 2011. He is currently the Research Director of Northern Almeria Health Area and Honorary Associate Professor of Malaga University. He has published more than 15 papers in the fields of Epidemiology.

Diabetes

Haipeng Xiao, M.D. Ph.D. Professor of Endocrine, Chief Expert President, the First Affiliated Hospital of Sun Yat-sen University Member of American Thyroid Association (ATA) Member of Continuing Medical Education (CME) Committee, American Endocrine Society Member of Association for Medical Education in Europe (AMEE) Vice Secretary General, Clinical Teaching Committee of Medical Education, Ministry of Education, P. R. China Vice President, China Endocrine and Metabolism Association, Chinese Medical Doctor Association President, Guangdong Endocrine and Metabolism Association, Chinese Medical Doctor Association Vice President, Guangdong Endocrine Society, Chinese Medical Association Member of Editorial Board, Chinese Medical Journal Member of Editorial Board, Chinese Journal of Endocrinology and Metabolism Member of Editorial Board, Chinese Journal of Diabetes Member of Editorial Board, Cardiovascular Endocrinology

As a long-term researcher in endocrine and metabolic diseases, Professor Xiao has published over 50 papers in core Chinese and foreign periodicals such as Journal of Clinical Endocrinology & Metabolism (JCEM), Brain Research, etc. Moreover, he took the lead in treating Graves’ diseases by introducing thyroid arterial embolization, and for the first time ever, he reported relevant findings of using innovative methods to treat Graves’ diseases in the prestigious Journal of JCEM. His clinical treatments of American and British patients with stubborn hyperthyroidism have been proved very successful and specially reported by CNN, causing profound international resonance. In June of 2012, he published another academic thesis “Circulating MicroRNA Profiles as Potential Biomarkers for Diagnosis of Papillary Thyroid Carcinoma” in JCEM which has received high attention and positive response among medical scientists home and abroad.

Dr. Yousef Shahin is a Chief Disease Prevention and Control, Health Department, United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), Jordan. After graduating in Medicine and General Surgery at Zaprozyha Medical University in the Former USSR in 1985, he joined Jordan University of Science and Technology where he completed Master degree in Public Health in 1995.Dr. Shahin was designated to World Health Organization/ Eastern Mediterranean Region from July-December 2011 as Technical Officer on non- communicable diseases. He has publications in medical journals including the Lancet on different health topics mainly diabetes care among Palestine Refugees. Participated in many international conferences and workshops addressing public health related topics.

Diabetes

Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. Dr Sanjeevi obtained his MD from India, PhD from KI in 1994 and did post-doc at the University of Washington in Seattle during 1994-1995 and has been at KI since then. Sanjeevi heads a research group at the Center for Molecular Medicine in KI. He is editor for the 'Immunology of Diabetes' series volumes (1 to 5) published by The Annals of the New York Academy of Sciences and served in the Editorial board of several journals like Diabetologia, Human Immunology, Current Diabetes Reviews Islets etc. Sanjeevi also served in the Council of the European Association for the Study of Diabetes (EASD) and had won several awards in the field of Diabetes from EASD and diabetes research foundations. He is visiting professor in several universities. He is also the secretary of the Immunology of Diabetes Society. Since 2000, he has served as KI's scientific coordinator for India and promoted Academy-Academy, Academy-Industry and Industry-Industry partnerships between KI and India as well as Sweden and India. Since 2006, he has been Senior advisor to Business Sweden, an agency that belongs to Ministry of Foreign Affairs, Govt of Sweden. He is also Senior Advisor to the Innovation Office of KI and promotes Ideas to IPs and find Indian investment partners for such IPs.

Diabetes, Diabetic Immunology

While heading a Medical college devoted to Diabetes education as Principal, triply post graduate in Medicine (MD), Nutrition (PGDND) and Radiology (DMRE), 64 years old Dr. Lakshmi K Shankhdhar, holds the credit of establishing North India’s first exclusive Diabetes Clinic in Lucknow, India. He is the fourth Indian to receive Wockhardt-Harvard Medical Excellence Award and Visiting Fellowship of Harvard Medical International, the International Arm of Harvard Medical School (Boston). He has presented several abstracts and Faculty orations in many International conferences on Diabetes and Podiatry, besides chairing some International conferences. Currently he is also reviewer of the journals of American Diabetes Association, namely Diabetes care and Diabetes.

Diabetes

Farhad Rezaee is a senior scientist at Erasmus Medical Center Rotterdam/University Medical Center Groningen. He received his Ph.D. at Medical University of Leiden in the Netherlands. Dr. Rezaee is a Systems Biologist (clinical genomics and proteomics) with focus on the discovery of defined and convinced clinical Biomarkers for every disease in human blood. His major research focuses are: 1- Obesity, diabetes, CVDs and rare diseases, 2- Biomarkers, 3- link between adipocytes, plasma lipoproteins, pancreas, and liver with respect to energy metabolic disorders, and 4- Systems Biology and age-related diseases, prevention of diseases and/or extend healthy aging. Dr. Rezaee is convinced that Systems Biology is the key to all medical and biological questions as well as all diseases. Last but not least, the 20 years’ experience and excellent Systems Biology expertise of Dr. Rezaee is lead to the development of a novel methodology, which is guarantee for the discovery of defined clinical Biomarkers for every disease in human blood by BCB.

Molecular Biology, Cell Biology, Systems Biology, Diabetes Mellitus Type 2, Vascular Biology, Type 1 Diabetes Mellitus

Dr Sebastian Oltean studied clinical medicine at “Iuliu Hatieganu” Medical School in Cluj- Napoca, Romania followed by training in Nephrology and Dialysis. He then moved to USA where in 2004 obtained a PhD in Biochemistry from the University of Nebraska-Lincoln, followed by postdoctoral training at Duke University Medical Center, where he studied connections between alternative splicing regulation and disease. In 2008 he moved to University of Bristol (UK) where he is now a University research fellow and principal investigator. One of his main research themes is the understanding of therapeutic potential of targeting alternative splicing in diabetic nephropathy.

My main research interests include the study of alternative splicing in vivo, coordinated regulation of alternative splicing in physiology and disease as well as manipulation of splice isoforms choice for therapeutic goals. Alternative splicing is the main process that decides the diversity of proteins in our bodies. It is estimated that more than 90% of genes are alternatively spliced in humans and therefore this process affects all cellular properties. The function of the majority of splicing isoforms is not characterized yet. Numerous splicing isoforms have been associated with disease progression in recent years and there is much interest in understanding their contribution to pathogenesis and how this can be reversed.